Iovance Biotherapeutics (IOVA) announced updated clinical results from a cohort of the phase II IOV-COM- 202 study evaluating the combination of its recently approved cell therapy Amtagvi and Merck’s blockbuster oncology drug Keytruda in frontline advanced melanoma. Based on a recent data cut that included 23 patients, treatment with the Amtagvi/Keytruda combo achieved a confirmed objective response rate (ORR) of 65.2%, including a complete responses (CR) rate of 30.4%. Management noted that ‘nearly all’ re ...